Business Context and Reporting Period
This Form 8-K was filed by Cyclacel Pharmaceuticals, Inc. on September 10, 2013. The report discloses a corporate action regarding the declaration of a quarterly cash dividend on the Company's 6% Convertible Exchangeable Preferred Stock.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is the dividend amount.
- Dividend Declared: $0.15 per share on 6% Convertible Exchangeable Preferred Stock.
- Record Date: October 21, 2013.
- Payment Date: November 1, 2013.
Material Changes
The filing reports the declaration of a dividend as a discrete event. It does not contain comparative financial data or material changes in operating results versus prior periods.
Guidance, Outlook, and Risks
Management noted that the Board considered financial analysis and surplus determination before declaring the dividend. The filing explicitly states there is no assurance that future quarterly dividends will be declared, as the Board will analyze the advisability of such declarations in future quarters.
Investor Verification Checklist
- Verify the number of outstanding shares of 6% Convertible Exchangeable Preferred Stock to calculate total dividend liability.
- Confirm the Company's current cash position and surplus status to assess the ability to fund the November 1, 2013 payment.
- Review the terms of the Preferred Stock to understand conversion rights and cumulative dividend obligations.
- Check subsequent filings for confirmation of the dividend payment or any changes to the record date.